Omitting bolus 5-fluorouracil (5-FU) from combination chemotherapy for gastrointestinal (GI) cancers did not adversely affect survival and was associated with less toxicity, a review of a large ...
The FDA added a boxed warning to capecitabine and 5-FU labels, noting the risk of serious adverse reactions or death in patients with complete DPD deficiency. Capecitabine and 5-FU are both nucleoside ...
June 17, 2009 (Orlando, Florida) — There is now an antidote for clinicians to use in the event of an overdose of the commonly used chemotherapy 5-fluorouracil (5-FU), according to a poster ...
A new case report was published in Volume 12 of Oncoscience on December 23, 2025, titled "Silent toxicity: A rare case of 5-fluorouracil-induced hyperammonemic encephalopathy." In this report, Areti ...
“The patient’s symptoms resolved after permanently stopping 5-FU and administering lactulose and intravenous fluids, therefore supporting the diagnosis of hyperammonemic encephalopathy due to 5-FU.” ...
Purple Biotech Ltd. announced a significant study revealing that their drug NT219, combined with 5-fluorouracil (5-FU), effectively inhibits colorectal cancer brain metastasis by targeting the IRS2 ...
Reducing regorafenib toxicity by combining with dual JAK-HDAC inhibitor in colorectal cancer. Safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by ...
Omitting the 5-fluorouracil (5-FU) bolus from multidrug regimens in patients with advanced gastrointestinal cancers reduces toxicities, such as cytopenia, and does not affect overall survival. Initial ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Administration of 5-FU bolus did not affect survival for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results